POINT Biopharma to Host Investor Education Event, “Understanding the PNT2002 Phase 3 SPLASH Trial Control Arm”, on August 18, 2022
The event will prepare investors for the release of SPLASH’s lead-in cohort efficacy data later…
The event will prepare investors for the release of SPLASH’s lead-in cohort efficacy data later…
LAWRENCEVILLE, N.J., Aug. 08, 2022 (GLOBE NEWSWIRE) — Celsion Corporation (NASDAQ: CLSN), a clinical-stage development company…
Multiple development and data milestones expected from seclidemstat and SP-3164 programs in 2H22 Conference call…
Extends Rani’s projected cash runway into mid-2024 SAN JOSE, Calif., Aug. 08, 2022 (GLOBE NEWSWIRE)…
Glen Rock, N.J., Aug. 08, 2022 (GLOBE NEWSWIRE) — RespireRx Pharmaceuticals Inc. (OTCQ:RSPI) (“RespireRx” or…
SAN DIEGO, Aug. 08, 2022 (GLOBE NEWSWIRE) — TRACON Pharmaceuticals, Inc. (Nasdaq: TCON), a clinical…
-CLIMB-111 and CLIMB-121 fully enrolled; completed regulatory discussions for exagamglogene autotemcel (exa-cel), formerly known as…
Non-executive director to bring extensive life science industry and finance experience SOUTH SAN FRANCISCO, Calif.,…
WALTHAM, Mass., Aug. 08, 2022 (GLOBE NEWSWIRE) — Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology…
BOTHELL, Wash., Aug. 08, 2022 (GLOBE NEWSWIRE) — Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or…
TORONTO, Aug. 08, 2022 (GLOBE NEWSWIRE) — Spectral Medical Inc. (“Spectral” or the “Company”) (TSX:…
SEATTLE, Aug. 08, 2022 (GLOBE NEWSWIRE) — Impel Pharmaceuticals Inc. (NASDAQ: IMPL), a commercial-stage pharmaceutical…
SAN DIEGO, Aug. 08, 2022 (GLOBE NEWSWIRE) — Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a biopharmaceutical…
Conference call to be held today, August 8, 2022 at 8:30 AM ET NEW YORK,…
New York, NY, and Tel Aviv, ISRAEL, Aug. 08, 2022 (GLOBE NEWSWIRE) — via NewMediaWire — Todos…
Positive topline data in the Phase 2 BrigHtn trial, demonstrating clinically meaningful and statistically significant…
~ Announced 12-month data on the lower-dose cohort of AMT-130 in Huntington’s disease showed the…
Successfully met the primary endpoint in the BrigHtn trial, delivering a 20.3 mmHg reduction in…
Phase 1 Study of TNX-801, a Vaccine in Development for the Prevention of Monkeypox and…
Net Product Sales Increase 40% Year-Over-Year, Non-GAAP Adjusted EBITDA Increases to $22.9 million Raises Full…